PMID- 15913885
OWN - NLM
STAT- MEDLINE
DCOM- 20051122
LR  - 20061115
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 228
IP  - 1-2
DP  - 2005 Oct 18
TI  - Diversity in neuroblastomas and discrimination of the risk to progress.
PG  - 267-70
AB  - The clinical diversity of Neuroblastomas (NBs) was discriminated into three 
      groups with high sensitivity and specificity to patient's outcome. The 'high 
      risk' NB is defined with any of following conditions, MYCN amplification or 
      unfavorable histology of International Neuroblastoma Pathological Classification 
      (INPC) or low Ha-ras/trk A expression. The 'low risk' NB is defined with all 
      following conditions, single copy of MYCN and INPC favorable histology and high 
      Ha-ras/trk A expression and localized tumor. The remaining NBs were classified 
      into 'intermediate risk' ones. According to these criteria, the diversity of the 
      248 mass-screening NBs was shown with variety progressive risk; 40% were 
      classified in low risk group, 25% were in high risk group and 35% were in 
      intermediate risk group.
FAU - Tanaka, Takeo
AU  - Tanaka T
AD  - Department of Pediatrics and Division of Clinical Research, National Hospital 
      Organization, Kure Medical Center, Hiroshima, Japan. ttanaka@kure-nh.go.jp
FAU - Iehara, Tomoko
AU  - Iehara T
FAU - Sugimoto, Tohru
AU  - Sugimoto T
FAU - Hamasaki, Minoru
AU  - Hamasaki M
FAU - Teramukai, Satoshi
AU  - Teramukai S
FAU - Tsuchida, Yoshiaki
AU  - Tsuchida Y
FAU - Kaneko, Michio
AU  - Kaneko M
FAU - Sawada, Tadashi
AU  - Sawada T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
SB  - IM
MH  - *Disease Progression
MH  - Humans
MH  - Mass Screening
MH  - Neuroblastoma/*pathology
MH  - Sensitivity and Specificity
RF  - 15
EDAT- 2005/05/26 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/05/26 09:00
PHST- 2004/11/26 00:00 [received]
PHST- 2004/12/02 00:00 [accepted]
PHST- 2005/05/26 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/05/26 09:00 [entrez]
AID - S0304-3835(05)00324-1 [pii]
AID - 10.1016/j.canlet.2004.12.051 [doi]
PST - ppublish
SO  - Cancer Lett. 2005 Oct 18;228(1-2):267-70. doi: 10.1016/j.canlet.2004.12.051.